You just read:

Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC)

News provided by

Nektar Therapeutics

Feb 05, 2013, 08:30 EST